Description
Ribociclib, marketed under the brand name Kryxana, It is an prescription medication that has been approved ribociclib (Kisqali) on March 13, 2017 for the treatment of advanced or metastatic breast cancer in postmenopausal women. The FDA granted the application a priority review and breakthrough therapy designation.
What is KRYXANA (Ribociclib) ?
Kryxana 200mg Tablet is used in the treatment of metastatic breast cancer. It helps to slow down the growth of cancer cells and eventually kills them.
Ribociclib was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and the European Medicines Agency (EMA) in August 2017, for use in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or metastatic breast cancers. In the clinical trial relevant for the drug’s approval, ribociclib significantly improved progression-free survival (PFS), that is, the time span the cancer did not get worse. For patients receiving placebo plus letrozole, PFS was 16 months on average, while under ribociclib plus letrozole, PFS was 25 months as of the January 2017 analysis. The study is scheduled to run until September 2020.
How to order approved “KRYXANA (Ribociclib) for tablets” Medicine?
Kryxana (Ribociclib) Tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing Kryxana and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
